Halozyme Therapeutics (NASDAQ:HALO) Releases FY 2024 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided EPS guidance of 4.000-4.200 for the period, compared to the consensus EPS estimate of 4.140. The company issued revenue guidance of $970.0 million-$1.0 billion, compared to the consensus revenue estimate of $1.0 billion. Halozyme Therapeutics also updated its FY 2025 guidance to 4.950-5.350 EPS.

Wall Street Analysts Forecast Growth

HALO has been the topic of several analyst reports. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Wells Fargo & Company lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their price target for the company from $58.00 to $62.00 in a research report on Monday, October 7th. JMP Securities increased their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. HC Wainwright restated a “buy” rating and set a $68.00 target price on shares of Halozyme Therapeutics in a research report on Monday, December 30th. Finally, JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price target for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $61.11.

Halozyme Therapeutics Trading Up 5.0 %

HALO stock opened at $53.76 on Friday. The company has a market capitalization of $6.84 billion, a price-to-earnings ratio of 17.80, a PEG ratio of 0.44 and a beta of 1.24. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. Halozyme Therapeutics has a 1-year low of $33.15 and a 1-year high of $65.53. The business has a 50 day simple moving average of $50.16 and a two-hundred day simple moving average of $54.00.

Insiders Place Their Bets

In related news, Director Jeffrey William Henderson sold 10,000 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the transaction, the director now owns 43,611 shares in the company, valued at $2,180,986.11. The trade was a 18.65 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.